Showing 3671-3680 of 6808 results for "".
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Bio-Oil Celebrates Body Confidence Through Body Positivity Month Campaignhttps://practicaldermatology.com/news/bio-oil-celebrates-body-confidence-through-body-positivity-month-campaign/2461538/Bio-Oil is rolling out a month-long campaign in celebration of February's Body Positivity Month to encourage self-love, promote body confidence, and highlight the role that Bio-Oil plays in helping people to love their stretch marks due to pregnancy, to scars from surgical procedur
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Laura Geller Beauty's Signature Foundation Scores the National Psoriasis Foundation's Seal of Recognitionhttps://practicaldermatology.com/news/laura-geller-beautys-signature-foundation-scores-the-national-psoriasis-foundations-seal-of-recognition/2461533/The National Psoriasis Foundation granted its Seal of Recognition to Laura Geller Beauty's Signature Baked Balance-n-Brighten Color Correcting Foundation. This is the first makeup product to receive the National Psoriasis Foundation Seal of Recognition.
- Bristol Myers Squibb Receives Positive CHMP Opinion for Once-Daily Sotyktu as Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/bristol-myers-squibb-receives-positive-chmp-opinion-for-once-daily-sotyktu-as-plaque-psoriasis-treatment/2461522/Four months after receiving FDA approval, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib; Bristol Myers Squibb) for the treatment of adults with moderate-to-severe plaque psoriasis. 
- Revealed: The Genetic Basis of 13 Pigment Traits and Their Relationship with Diseaseshttps://practicaldermatology.com/news/revealed-the-genetic-basis-of-13-pigment-traits-and-their-relationship-with-diseases/2461515/Researchers have uncovered the genetic basis of 13 pigment traits and their association with diseases. Using the GCAT cohort, researchers built a comprehensive analysis strategy leading to the identification of phototype associated-diseases in a total of nearly 20,000 Ca
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Beekman 1802 Pledges to Put Nurses First in 2023https://practicaldermatology.com/news/beekman-1802-pledges-to-put-nurses-first-in-2023/2461487/Beekman 1802 is launching "